Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SANA · against 488 other Healthcare companies of similar size
Ranked #321 of 489 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score169 peers with a valuation score of 0–9, including SANA · Click a bar to see the companies
Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | SANA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 477 reported | -30.7% | 1.0% | 5% | 30% | |
| EBITDA yieldHigher is better · 494 reported | -26.8% | 3.7% | 8% | 50% | |
| Free cash flow yieldHigher is better · 202 reported | -18.5% | -3.5% | 18% | 20% | |
| Book yieldHigher is better · 485 reported | 21.1% | 45.3% | 20% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 321 | 1.2B USD | 8 | 40 | |
| 321 | 474M USD | 8 | 25 | |
| 321 | 504M USD | 8 | 24 | |
| 321 | 388M USD | 8 | 36 | |
| 321 | 730M USD | 8 | 11 | |
| 321 | 468M USD | 8 | 40 | |
| 321 | 519M USD | 8 | 22 | |
| 321 | 1.2B USD | 8 | 40 | |
| 321 | 1.1B USD | 8 | 50 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score